Protease Inhibitors: all 1,856 studies that test it
Page 11 of 19. Open to participants first (69), then studies with results posted, then the rest; newest registration first within each.
- Impact of Hepatitis C Therapy and Bone HealthTerminatedNCT03221582Phase 4
- Bioequivalence Study (Preliminary Study) of Ritonavir Versus NORVIR in Healthy Chinese SubjectsCompletedNCT03214159Phase 1
- A Relative Bioavailability Study of Two Formulations of BCX7353CompletedNCT03202784Phase 1
- Sofosbuvir and Daclatasvir in Treating Hepatitis C, A Study on 1000 PatientsCompletedNCT03200184Phase 4
- The Relationship Between MDSCs and NK Cells Activity of CHC Patient Treated by DAAsCompletedNCT03188276Early Phase 1
- 8 Weeks Versus 12 Weeks of Elbasvir/Grazoprevir in Treatment-naïve CHC With Mild FibrosisCompletedNCT03186365Phase 3
- A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)TerminatedNCT03173092Phase 4
- Assessment Effects After Direct Acting Antiviral in Chronic Hepatitis c Virus PatientsStatus unknownNCT03163849Phase 3
- Using Less Neurotoxic Drugs in Patients With HAND (MARAND-X)TerminatedNCT03163277Phase 4
- Ulinastatin Improves Postoperative Oxygenation After Cardiopulmonary BypassCompletedNCT03154814Phase 4
- Study to Compare Bioavailability of GLPG1972 Given as 2 Different Tablet Formulations Versus an Oral SolutionCompletedNCT03143725Phase 1
- A Drug-Drug Interaction Study to Evaluate Drug Transporter InteractionsCompletedNCT03136237Phase 1
- the Effect of Grazoprevir/Elbasvir and TACE vs. TACE Alone in Prolonging Survival of Patients With Non-resectable HCV Associated HCC.Status unknownNCT03110055Not applicable
- A Clinical Trial of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotypes 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5AWithdrawnNCT03105349Phase 4
- Optimization of Darunavir Therapy and Dosage RecommendationsCompletedNCT03101644Phase 4
- Efficacy and Tolerability of Grazoprevir and Elbasvir in Patients With Chronic Genotype 1 HCV and HIV Co-infectionCompletedNCT03098121Phase 4
- The Pharmacokinetics of Dolutegravir, Darunavir/Cobocistat When Co-administered in Healthy VolunteersCompletedNCT03094507Phase 1
- Direct-acting Antiviral Therapy to Prevent HCV Infection for HCV Positive Donor to HCV Negative Recipient Kidney TransplantWithdrawnNCT03093740Phase 4
- Prevention of Ulinastatin on Acute Respiratory Distress Syndrome (ARDS)CompletedNCT03089957Not applicable
- Efficacy and Safety of Gosogliptin as Monotherapy and in Combination With Metformin vs. Vildagliptin as Monotherapy and in Combination With Metformin in Drug-naive Type 2 Diabetic Patients.CompletedNCT03088670Phase 3
- Efficacy and Safety of Qurevo Plus Ribavirin Based Therapy for Hepatitis C With or Without Cirrhosis in Haemodialysis PatientsStatus unknownNCT03067883Phase 2
- Preemptive Zepatier Treatment in Donor HCV Positive to Recipient HCV Negative Cardiac TransplantWithdrawnNCT03026023Phase 4
- Safety and Effect of Elbasvir/Grazoprevir Combination Therapy in Hemodialysis Patients With Chronic Hepatitis CStatus unknownNCT03022006Phase 4
- Pharmacokinetics and Safety of Ravidasvir and Danoprevir/r in Healthy Volunteers ChinaCompletedNCT03020134Phase 1
- Safety, Tolerability and Pharmacokinetics of Danoprevir/r in Healthy Volunteers ChinaCompletedNCT03019991Phase 1
- Dolutegravir and Darunavir Evaluation in Adults Failing TherapyStatus unknownNCT03017872Phase 4
- Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without NS5A RAVCompletedNCT03004625Phase 3
- Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast CancerTerminatedNCT02993094Phase 1/2
- Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C InfectionCompletedNCT02992457Phase 4
- Study to Evaluate the Relative Bioavailability of Fixed-dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) as a Whole Tablet, as a Split Tablet, and as Crushed Tablet in Healthy Adult ParticipantsCompletedNCT02984852Phase 1
- A Study of Lonafarnib With or Without Ritonavir in Patients With HDVWithdrawnNCT02968641Phase 2
- Strategic Transformation of the Market of HCV TreatmentsStatus unknownNCT02961426Phase 2/3
- Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic LeukemiaCompletedNCT02948283Phase 1
- A Pharmacokinetic Interaction Study Between Odalasvir, Given as a Single Agent or in Combination With Simeprevir, and Dabigatran Etexilate Mesylate in Healthy ParticipantsCompletedNCT02945020Phase 1
- Study of Ixazomib and Erlotinib in Solid TumorsCompletedNCT02942095Phase 1
- Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS SyndromeCompletedNCT02921893Early Phase 1
- Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Plus Lenalidomide Maintenance in Multiple MyelomaTerminatedNCT02897830Phase 2
- Efficacy of GZR/EBR in Early Chronic Hepatitis C in HIV/HCV Co-infected PatientsStatus unknownNCT02897596Phase 3
- The Dublin Zepatier StudyTerminatedNCT02895958Phase 4
- The Safety and Dose Response Relationship of Ulinastatin for Acute Respiratory Distress Syndrome(ARDS)Status unknownNCT02895191Phase 2
- Pilot Study Evaluate Efficacy of Grazoprevir + Elbasvir for 12 or 16 Weeks in Liver Transplant Recipients.WithdrawnNCT02890719Phase 3
- Recombinant Human C1 Esterase Inhibitor in the Prevention of Contrast-induced Nephropathy in High-risk SubjectsCompletedNCT02869347Phase 2
- Bioavailability Study With GLPG1972CompletedNCT02851485Phase 1
- A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With MyelomaCompletedNCT02831686Phase 1
- Study to Investigate the Pharmacokinetic Interaction Between 2 Direct Acting Antiviral Agents Odalasvir and AL-335 and Between 3 Direct Acting Antiviral Agents Simeprevir, Odalasvir and AL-335 at Steady State in Healthy Japanese ParticipantsCompletedNCT02824315Phase 1
- Clinical Trial to Evaluate Drug-drug Interactions Between Darunavir/Cobicistat and Etravirine in Hiv- Infected PatientsCompletedNCT02818348Phase 1
- Study of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection With End Stage Renal Disease (ESRD) on Hemodialysis (HD)WithdrawnNCT02806362Phase 3
- Swiss HCVree TrialCompletedNCT02785666Phase 3
- Bioequivalence Study of Daclatasvir From Prodactariv 60 mg Film Coated Tablets (International Drug Agency for Pharmaceutical Industry (IDI), Egypt) and Clatazev 60 mg Tablets (Bristol-Myers Squibb Pharma, UK)CompletedNCT02780362Phase 1
- Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCCCompletedNCT02771405Phase 3
- Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy VolunteersCompletedNCT02771249Phase 1
- Bioequivalence Study of Daclatasvir From Daclatasvir Zeta 60 mg Film Coated Tablets (Zeta Pharm Pharmaceutical Industries, Egypt) and Clatazev 60 mg Tablets (Bristol-Myers Squibb Pharma, UK)CompletedNCT02756936Phase 1
- Effects of Empagliflozin + Linagliptin vs Metformin + Insulin Glargine on Renal and Vascular Changes in Type 2 DiabetesCompletedNCT02752113Phase 3
- A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid TumorsCompletedNCT02743637Phase 1
- Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase InhibitorsCompletedNCT02738502Phase 2
- Study to Investigate Tolerability and Efficacy of MK5172 / MK8742 Without Ribavirin for 12 Weeks in Patients With Chronic HCV G1b Infection With Compensated CirrhosisStatus unknownNCT02732405Phase 3
- A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus InfectionCompletedNCT02716428Phase 2
- Antiretroviral Regime for Viral Eradication in NewbornsCompletedNCT02712801Phase 4
- Pharmacokinetic Effect of Evotaz/Microgynon Co-administrationTerminatedNCT02697851Phase 1
- Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot StudyCompletedNCT02697383Phase 1
- Bioequivalence Study of Daclatasvir From Daktavira 60 mg Film Coated Tablets ( European Egyptian Pharmaceutical Industries, Egypt) Versus Daklinza 60 mg Tablets (Bristol-Myers Squibb Pharma, UK)CompletedNCT02675127Phase 1
- Evaluation of Low-dose Darunavir in a Switch StudyCompletedNCT02671383Phase 3
- Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell TransplantationActive, not recruitingNCT02669251Phase 1/2
- Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With SofosbuvirCompletedNCT02647632Phase 2
- Ulinastatin Treatment in Adult Patients With Sepsis and Septic Shock in ChinaCompletedNCT02647554Phase 4
- Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/PCompletedNCT02634008Phase 3
- Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in RemissionActive, not recruitingNCT02632396Phase 1/2
- PK of Efavirenz & Lopinavir Nano-formulations in Healthy VolunteersSuspendedNCT02631473Phase 1
- Randomized Clinical Trial of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus Genotype 1 (TNT)CompletedNCT02624063Phase 4
- First-in-Human Single and Multiple Dose of GLPG1972CompletedNCT02612246Phase 1
- Sofosbuvir, Daclatasvir, Ribavirin for Hepatitis C Virus (HCV) CirrhoticsCompletedNCT02596880Phase 3
- SSAT067 PK of Atazanavir/Cobicistat and Darunavir/CobicistatCompletedNCT02589158Phase 1
- MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of AgeCompletedNCT02582359Phase 1
- The Safety and Efficacy of Daclatasvir and Asunaprevir With Chronic HCV Genotype 1b Infection and Chronic Renal FailureCompletedNCT02580474Phase 4
- A Bioequivalence Study of Darunavir, Emtricitabine, and Tenofovir Alafenamide, in the Presence of Cobicistat in Healthy ParticipantsCompletedNCT02578550Phase 1
- Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed Phenotype Acute Leukemia in Complete Remission (CR)WithdrawnNCT02578511Phase 1
- UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD CombinationWithdrawnNCT02578121Phase 2
- Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT3 Infected PatientsCompletedNCT02576314Phase 3
- Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive ImpairmentTerminatedNCT02573740Phase 1
- Pharmacokinetics of Atazanavir /Dolutegravir/Lamivudine Regimen as Maintenance RegimenTerminatedNCT02566707Phase 2
- A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/CobicistatCompletedNCT02565888Phase 1
- A Drug-drug Interaction Study Between Daclatasvir and MetforminCompletedNCT02565862Phase 1
- A Phase 2b Evaluation of Daclatasvir/Sofosbuvir in Non-Cirrhotic Treatment Naive Subjects With Genotype 1, 2, 3 and 4 Chronic Hepatitis C Virus Coinfected With Human Immunodeficiency Virus (HIV-1)WithdrawnNCT02556086Phase 2
- DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)CompletedNCT02555943Phase 2/3
- A Study of a Nucleoside Sparing Regimen in HIV-1 Infected Patients With Detectable ViremiaCompletedNCT02542852Phase 2
- Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients with Multiple MyelomaActive, not recruitingNCT02542657Phase 1/2
- Ulinastatin Injection in in Pediatric Patients Undergoing Open Heart SurgeryStatus unknownNCT02527811Phase 4
- Aralast NP in Islet TransplantCompletedNCT02520076Phase 1/2
- Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple MyelomaCompletedNCT02504359Phase 1
- Effect of Cobicistat Versus Ritonavir Boosting on the Brain Permeation of Darunavir in HIV-infected IndividualsTerminatedNCT02503462Phase 4
- Darunavir/Cobicistat and Dolutegravir to Maintain Virologic Suppression and Reduce NRTI-associated ToxicityWithdrawnNCT02499978Phase 2/3
- A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b InfectionCompletedNCT02496078Phase 3
- Study in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of VM-1500CompletedNCT02489487Phase 1
- Safety, Tolerability, and Efficacy of 24 Weeks Simeprevir+Sofosbuvir for Chronic Hepatitis C Genotype 1WithdrawnNCT02485080Phase 4
- Relative Bioavailability and Food Effect for Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed Dose CombinationCompletedNCT02475135Phase 1
- Study Evaluating the Efficacy of a Reduced Dose Atazanavir in HIV-1-infected PatientsCompletedNCT02473328Phase 2
- SOF Plus DCV in Treating Chinese Treatment-experienced HCV PatientsCompletedNCT02473211Phase 2/3
- Neurocognitive Performance and Emotional State in HCV Patients With IFN-free Antiviral TherapyStatus unknownNCT02469012Not applicable
- Phase II Randomised Trial of Cyclophosphamide & Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.CompletedNCT02461888Phase 2
- Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV TreatmentActive, not recruitingNCT02460133Phase 4